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Δ32-CCR5 heterozygosityutely infected with a genetically almost identical virus, allowed us to investigate
genetic variability and disease progression in early HIV-1 infection with minimal interference of virus speciﬁc
factors. Two of the patients were heterozygous for the 32-bp deletion in the CCR5 coreceptor gene. Both
showed a slower disease progression with lower viral load levels and a reduced rate of genetic evolution
compared to the patients with normal CCR5 alleles. During 3 years of treatment-free follow-up, the mean
pairwise genetic distance increased with 1.45% and 1.58% in the two patients with a 32-bp deletion allele
compared to 3.05% and 3.57% in the two patients with normal CCR5 alleles. The observed relation between
slower disease progression and a reduced evolutionary rate illustrates the inﬂuence of the virus replicative
capacity, here most possibly hampered by the CCR5 heterozygosity in two of the four individuals, on the
genetic evolution of the virus in the host.
© 2008 Elsevier Inc. All rights reserved.Introduction
In the absence of antiretroviral therapy, the rate of disease
progression inHIV-1 infected individuals can be very different, ranging
from progression to AIDS within 1 year to long-term asymptomatic
survival for over 15 years. It is becoming clear that people with long-
term non-progressive infection represent a heterogenous group with
non-progression being the result of either infection with a genetically
unique virus, an unusually effective immune response, a unique host–
virus relation or a combination of these (Deacon et al., 1995; Kirchhoff
et al., 1995). The most documented host genetic factor inﬂuencing
disease progression is a 32-bp deletion from the chemokine CCR5
receptor gene (Husman et al., 1997).
HIV-1 exhibits signiﬁcant genetic diversity, between hosts as well
as within the same individual (Shankarappa et al., 1999). Soon after
infection the majority of infected individuals harbour a homogeneouslmet),
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l rights reserved.viral population from which a quasispecies evolves over time (Zhu et
al., 1993). The ability to generate genetic diversity allows the virus to
escape from selection pressures such as the host immune response
and antiretroviral drugs and enables the continuous evolution
towards the highest degree of ﬁtness. The most variable regions are
localized in the viral env gene. This gene encodes for the virion
surface glycoproteins gp120 and gp41, that are involved in the
interaction between the virus and the target cell. Envelope
glycoproteins also have an important role in viral ﬁtness (Ball et al.,
2003; Marozsan et al., 2001; Rangel et al., 2003) and are known
targets for neutralising antibodies (Parren et al., 1999) and CD8+ T cell
responses (Carmichael et al., 1996). Patients with slow disease
progression are supposed to have vigorous humoral and cellular
immune responses that drive the evolution of escape variants
(Goulder and Watkins, 2004). Results of several studies indicating a
higher degree of virus variation in slower clinical progression support
this assumption (Essajee et al., 1999; Ganeshan et al., 1997; Liu et al.,
1997; Lukashov et al., 1995; Wolinsky et al., 1996). Others however
reported a higher genetic diversity in rapid progressors than in slow
progressors (Hutto et al., 1996; Mani et al., 2002; Markham et al.,
1998; Strunnikova et al., 1995; Sutthent et al., 1998). The latter
support the hypothesis that viral diversity and antigenic variation is
mainly driven by viral replication.
The fact that conclusions of a signiﬁcant number of studies on
intra-host HIV variability are so contradictory indicates that the
Fig. 1. Phylogenetic tree constructed after analysis of the env C2–V3 sequence of the 4 study subjects and 25 at random selected individuals from the cohort of patients followed at the
hospital. Four subtype B reference strains were included. The subtype A reference strain AF286238 (A2.CD.97) was used as outgroup and root.
Table 1
Summary of the patients' characteristics
ID Patient A Patient B Patient C Patient D
CCR5 genotype CCR5-Δ32/wt CCR5-wt/wt CCR5-wt/wt CCR5-Δ32/w
HLA type A01_A02/
B13_B44
A24_A26A/
B07_B35
A02_A68/
B44_B53
A11_A29/
B35_B44
Age at infection 30 31 24 34
Date of the last negative
HIV test
Nov '01 Feb '02 Aug '01 Dec '01
Date of the ﬁrst positive
HIV test
Mar '02 Apr '02 Apr '02 Apr '02
Flu-like illness – Feb '02 Oct '01 –
Presumed infection date Before Mar
'02
Feb '02 Oct '01 Jan '02
Presumed source of
infection
Unknown Patient C Unknown Patient C
Date of inclusion
(=day 0)
04/10/2002 05/10/2002 05/14/2002 05/06/2002
Viral load at day 0
(copies/ml)
39,000 424,000 104,000 21,700
CD4 count at day 0
(cells/mm3)
523 259 361 820
HAART AZT+
3TC+ABC
AZT+
3TC+LPVr
AZT+
3TC+NFV
AZT+
3TC+ABC
Time to ﬁrst undetectable
viral load (in days)
112 143 122 55
Period on HAART 04/10/02–
04/24/03
05/10/02–
05/20/03
05/22/02–
05/22/03
05/06/02–
06/07/03
Viral load rebound
(1 month after stop)
8820 N100,000 36,100 36,100
Therapy resumed (date) No Yes (Oct '06) Yes (Sept '06) No
214 K. Chalmet et al. / Virology 379 (2008) 213–222relationship between variability and disease progression is complex
and still poorly understood. The study of epidemiological-linked HIV-
1 infected subjects might serve as the most appropriate model to
evaluate the importance of host factors on disease progression and on
the HIV variability, because it enables to control for the inﬂuence of
virus speciﬁc factors.
In the current studywe have analysed the disease progression and the
evolutionofHIV-1quasispecies variability in 4 individuals acutely infected
with closely related HIV-1 strains. Three of these individuals were also
epidemiologically linked. What makes this clustered cohort of particular
interest is the fact that 2 of the 4 subjects are heterozygous for the 32-bp
CCR5 deletion. The other 2 patients have twowild type CCR5 alleles. All 4
individuals were temporarily treatedwith antiretroviral therapy (ART) for
one year soon after diagnosis, after which the medication was stopped.
Besides a close monitoring of plasma viral load levels and CD4+ T cell
counts we performed an extensive analysis of the intrapatient genetic
diversity of the HIV-1 env gene over a period of 4 years.
Results
Phylogenetic relationship
Phylogenetic analysis of the 300-bp protease gene and a 619-bp
fragment of the reverse transcriptase (RT) gene from 198 patients
attending the Aids Reference Centre in our hospital, allowed the
identiﬁcation of a cluster of four patients infectedwith a closely related
HIV-1 strain of the B subtype (results not shown). For three of these
patients (B, C and D) a 100% identity of the PR/RT fragment was
observed. The viral strain isolated frompatient A showed an identity of
99.7%. To further support the genetic relationship, phylogenetic
analysis of the env gene was performed. The phylogenetic tree
shown in Fig. 1 is based on the comparison of the C2–V3 env region
for the 4 study subjects and for 25 other patients from the hospital
cohort with a documented acute subtype B infection as well as 4
subtype B reference strains (B.US.90.WEAU160.U21135, B.US.86.JRFL.
U63632, B.US.83.RF.M17451, B.FR.83HXB2-LAI-IIIB-BRU.K03455). The
tree was rooted using a subtype A reference strain (AF286238 — A2.CD.97). This analysis conﬁrmed the close genetic identity of the viral
strains in the four study subjects.
Viral load and CD4+ T cell count
All four patients received HAART, initiated shortly after their
ﬁrst consultation and continued without interruption for a period
of one year. Patients were further followed after treatmentt
215K. Chalmet et al. / Virology 379 (2008) 213–222interruption for 3 years. Reinitiating treatment was considered
necessary in patients B and C at the end of the follow-up period.
The initiative for restarting medication was made by the clinician
without knowledge of the ﬁndings described in this study. Fig. 2
illustrates the evolution of the viral load and the CD4+ T cell count
during the whole follow-up period. Table 1 summarizes the patient
characteristics. The two patients with the CCR5-Δ32 allele had
lower baseline viral loads and higher baseline CD4+ T cell counts
compared to the patients with wild type CCR5. The viral load
decreased to below detection limits within 55 to 143 days after
treatment initiation in all 4 patients. The mean viral load rebound
at one month after treatment interruption was lower for the two
CCR5-Δ32 heterozygotes compared to the patients with wild type
CCR5 (8820 copies/ml and 36,100 copies/ml versus 36,100 and
N100,000 copies/ml) but the difference was not signiﬁcant (p=0,7).
After viral rebound, the two CCR5-Δ32 patients were able to
suppress viral replication to a set-point level below this of the two
patients with wild type CCR5 alleles (see Fig. 2). The low viral load
levels were maintained over the whole 3 years of treatment-free
follow-up. In the CCR5-Δ32/wt patient D results of less than
1000 RNA copies/ml were obtained for most of the measurements.
The same patient was also able to conserve his CD4+ T cells
(lowest CD4+ T cell count: 800 cells/mm3). One of the patients
with a wt/wt CCR5 gene (patient B), showed a fast decrease of the
CD4+ T cell count after treatment interruption to values below
350 cells/mm3. In patients A (CCR5-Δ32/wt) and C (CCR5-wt/wt)
the CD4+ T cell counts ﬂuctuated between 500 and 800 cells/mm3.Fig. 2. Evolution of the viral load (□—) and CD4+ Tcell count (▴ --) over time in the 4 study sub
load remainedundetectable (b50 copies/ml) during the treatment period in all 4 patients. The
viral load of b50 copies/ml (log copies/ml b1.70). 3TC = lamivudine; AZT = zidovudine; ABCPhylogenetic analysis of the envelope gene
In order to characterize the genetic diversity and the genetic
evolution of the virus in the different hosts, single genome sequencing
of the V1–V4 env region from PBMC-derived viral DNAwas performed.
A relatively large env fragment of N1000 nucleotides was sequenced
from 4 to 5 samples of each patient, collected between the ﬁrst visit
(day 0), and 4 years thereafter (3 years after treatment interruption).
At least 10 individual sequences (between 10 and 19) were analysed
per sample. Limiting dilution PBMC-derived DNA sequences were
obtained for all samples collected. Additionally, clonal RNA sequences
were obtained for the plasma samples collected at baseline and
3 years after treatment interruption. An overall consensus sequence
was composed from all baseline sequences (DNA and RNA) and used
to root the phylogenetic trees (Fig. 3). The trees in Fig. 3 illustrate the
tight intermingling of the baseline sequences from patients B, C and D.
Baseline samples from patient A cluster away (Fig. 3A). The sequences
of the samples collected during the last visit form separate clusters for
all 4 patients, indicating a divergent evolution (Fig. 3B). Differences in
evolutionary rate for the 4 patients are apparent from the tree
topology. The trees also show the close intermingling of DNA and RNA
sequences for each of the 4 patients.
Analysis of the intra-sample sequence heterogeneity
The intra-sample virus heterogeneitywas assessedbycalculating the
mean pairwise genetic distance between the clonal sequences of thejects. HAARTwas initiated for 1 year starting soon after collection of theﬁrst sample. Viral
CD4+ Tcell count is expressed as cells/mm3. The viral load is expressed as log copies/ml. ◊:
= abacavir; LPV = lopinavir; NFV = Nelﬁnavir.
Fig. 2 (continued).
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baseline samples and in the samples collected one month after
treatment interruption (Table 2). The baseline heterogeneity was the
highest in patient A. Patient A was also the only patient with a slight
increase in heterogeneity between baseline and treatment stop. In the
other patients the heterogeneity was stable or decreased during the
one-year treatment period. After treatment interruption, the mean
pairwise genetic distance in PBMC-derived viral DNA increased with
1.58% (0.48%/yr) and 1.45% (0.49%/yr) in the two patients with a 32-bp
CCR5 deletion (patients A and D) and with 3.05% (0.97%/yr) and 3.57%
(1.26%/yr) in the two patients with normal CCR5 alleles (patients C and
B). The increase in virus heterogeneity correlateswith the set-point viral
load. The intrapatient virus heterogeneity in the last sample, collected
3 years after treatment interruption, was the highest for patient B
followedbypatient C,D andA (Table 2). Thepairwise comparisonsof the
differences in virus heterogeneity between patients were statistically
signiﬁcant for all but patients B and C (p=0.203). With exception of the
baseline sample for patient B, the genetic heterogeneityobserved for the
RNA and DNA sequences was identical.
Apart from differences as a result of point mutations, an increasing
number of insertions and deletions were observed over time,
especially in the V1–V2 region. In order to account for these insertions
and deletions as an additional contribution to the overall variability in
the env region, the mean fragment length and the range of the
fragment lengths for each sample was calculated (Table 2). Patient D
was the only patient in whom the total fragment length of the
different sequences remained almost constant. In the other patients a
clear trend towards increased fragment length was observed.Analysis of the genetic divergence
The genetic evolution in the individual patients over time was
assessed by calculating the mean pairwise genetic distance between
the sequences of the baseline sample and each of the follow-up
samples (Table 2). The evolution of the mean pairwise genetic
distances from baseline are illustrated in Fig. 4. Patient C is evolving
with the highest rate, followed by patient B, A and D. Differences in the
slopes of the regression line are statistically signiﬁcant for the
comparison between patients A and C, between patients B and D
and between patients C and D. There was a trend for a steeper curve
for patient B compared to patient A but this difference did not reach
statistical signiﬁcance (p=0.074). No differences in the shape of the
regression lines were observed for the two patients with a mutant
CCR5 (patients A and D; p=0.66) and for the two patients with wild
type CCR5 (patients B and C; p=0.20).
Discussion
This paper describes a cluster of 4 individuals acutely infected with
a highly related HIV-1 strain. Two of the subjects were shown to be
heterozygous for the 32-bp deletion in the CCR5 gene. The recent
onset of infection in all 4 was conﬁrmed by the observation of a
homogeneous virus population in the ﬁrst sample collected. Baseline
env sequences were tightly intermingled. Though it is impossible to
exclude that the founder virus for patients A and D was ‘less ﬁt’ than
the founder virus for patients B and C this possibility is considered
highly unlikely considering the close phylogenetic relation between
Table 2
Follow-up data on viral load, CD4 count, virus genetic evolution and virus heterogeneity
Patient ID CCR5
genotype
Collection
date
Day Sample Viral load CD4
count
Na Mean fragment lengthb
(range)
MPD from
baselinec
SD MPD within
sampled
SD
A Δ32 4/10/2002 0 DNA 39,000 523 14 1011.00 (1011–1011) – – 0.82 0.47
A 4/10/2002 0 RNA 39,000 523 43 1011.00 (1011–1011) – – 0.74 0.43
A 5/22/2003 402 DNA 8820 621 12 1010.75 (1008–1011) 0.99 0.47 1.07 0.46
A 4/28/2004 738 DNA 10,700 486 13 1007.08 (993–1011) 1.49 0.62 1.13 0.54
A 5/11/2005 1111 DNA 2990 378 11 1003.91 (987–1011) 1.40 0.63 1.54 0.71
A 9/13/2006 1593 DNA 1960 345 10 1016.10 (993–1062) 3.44 0.92 2.66 0.78
A 9/13/2006 1593 RNA 1960 345 44 1021.09 (1008–1041) – – 2.80 1.36
B WT 5/10/2002 0 DNA 424,000 259 12 1011.00 (1011–1011) – – 0.39 0.19
B 5/10/202 0 RNA 424,000 259 38 1011.00 (1011–1011) – – 0.70 0.27
B 6/20/2003 400 DNA N100,000 385 10 1011.00 (1011–1011) 0.37 0.18 0.20 0.13
B 11/17/203 547 DNA 68,300 646 10 1006.50 (999–1011) 0.64 0.25 0.91 0.34
B 5/26/2004 736 DNA 210,000 294 12 1009.50 (996–1014) 1.34 0.54 1.27 0.33
B 5/24/2005 1094 DNA 131,000 314 11 1024.36 (1011–1047) 2.64 1.09 2.68 0.89
B 5/3/2006 1433 DNA N100,000 315 10 1044.90 (1026–1053) 4.21 0.44 3.96 1.90
B 5/3/2006 1433 RNA N100,000 315 32 1044.75 (1005–1053) – – 3.94 2.47
C WT 5/14/2002 0 DNA 104,000 361 13 1009.39 (1008–1011) – – 0.65 0.23
C 5/14/2002 0 RNA 104,000 361 1009.87 (1008–1011) – – 0.73 0.28
C 6/23/2003 399 DNA 36,100 716 10 1011.00 (1011–1011) 0.61 0.27 0.45 0.28
C 11/28/2003 554 DNA 39,300 437 14 1010.79 (1008–1011) 1.22 0.40 1.01 0.44
C 3/31/2004 677 DNA 31,800 675 13 1024.62 (1011–1044) 1.93 0.59 1.64 0.53
C 9/24/2004 850 DNA 8200 600 14 1035.00 (1011–1053) 2.38 1.04 2.50 1.02
C 9/5/2006 1551 DNA 85,100 227 13 1043.54 (1032–1065) 6.42 1.27 3.50 1.90
C 9/5/2006 1551 RNA 85,100 227 45 1045.32 (1029–1065) – – 3.18 1.48
D Δ32 5/6/2002 0 DNA 21,700 820 17 1011.00 (1011–1011) – – 0.20 0.14
D 5/6/2002 0 RNA 21,700 820 1011.00 (1011–1011) – – 0.30 0.17
D 7/7/2003 421 DNA 36,100 1290 11 1011.00 (1011–1011) 0.16 0.12 0.13 0.09
D 3/26/2004 680 DNA 1710 1040 16 1011.00 (1011–1011) 0.41 0.28 0.54 0.30
D 8/2/2004 806 DNA 2050 1120 11 1011.27 (1011–1014) 0.78 0.25 0.64 0.23
D 2/1/2005 985 DNA 868 950 15 1011.00 (1011–1011) 0.84 0.37 0.72 0.22
D 2/28/2006 1372 RNA 315 851 40 1011.00 (1011–1011) – – 0.99 1.08
D 7/6/2006 1500 DNA 1240 969 18 1011.00 (1011–1011) 1.48 0.95 1.58 0.62
The viral load is expressed as copies/ml, the CD4+ T cell count is expressed as cells/mm3.
RNA samples are indicated in bold.
a number of single cell or clonal sequences used for the analysis.
b mean total nucleotide length of the fragments.
c % mean pairwise difference (MPD) between the baseline sequences (day 0) and the sequences of each of the follow-up samples.
d % intra-sample mean pairwise distance (MPD).
217K. Chalmet et al. / Virology 379 (2008) 213–222the viruses in all 4 individuals and the fact that the transmissions in
this cluster occurred during the early stage of infection at a timewhen
a relatively homogeneous virus population was present. The aim of
this study was to follow the disease process and to analyse the genetic
evolution of the virus over a 4-year time period as a way to assess the
inﬂuences of host genetics and more speciﬁcally the inﬂuence of the
CCR5 genotype on these processes.
The results of several studies indicate the importance of the host
genetic background in the HIV disease process (Draenert et al., 2006;
Hutto et al., 1996; Liu et al., 1997; Mikhail et al., 2005). Probably one of
the most intensively studied host–virus relations is the inﬂuence of
the CCR5 genotype. Analysis on large databases of individual patients
has shown that CCR5-Δ32/wt heterozygotes have a reduced risk for
progression to AIDS and lower viral loads, especially early in the
course of their disease (Ioannidis et al., 2001). The observations made
in the small clustered cohort presented here, conﬁrm these ﬁndings.
But, despite infection with an almost identical virus and the same
CCR5 genotype, individual differences in both disease progression and
viral load were observed, pointing to the possible inﬂuence of other
host factors. Our cohort was too small to study other genetic factors
such as the HLA type or to assess the inﬂuence of other STD infections.
No correlation between the viral load and virus heterogeneity was
observed in the ﬁrst samples collected from the patients although the
slowest progressor, patient D, already presented with the lowest viral
load and the most homogeneous virus population at baseline.
Comparison of the heterogeneity of the virus population before ART
and 1 month after ART interruption, showed a restriction of the genetic
evolutionduring treatment in 3 of the 4 patientswith a slight increase in
patient A. A stabilisation of the genetic diversiﬁcation during HAART
initiated in a later stage of infection has been reported (Troyer et al.,2005) but ongoing low level viral replication in the presence of HAART
can results in a further accumulation ofmutations (Gunthard et al.,1999)
and might explain the increase in heterogeneity observed in patient A.
After treatment interruption, the virus population steadily evolves to a
heterogeneous mixture, though with a different rate from patient to
patient. The divergence from the baseline sample over the 4 years of
follow-up was not signiﬁcantly different for the patients with the same
CCR5 genotype but a faster rate of divergence was observed for the two
CCR5-wt/wt patients compared to the CCR5-Δ32/wt. Also the intra-
sample virus heterogeneity determined in the last sample collectedwas
signiﬁcantly higher in the patients with CCR5-wt/wt than in the CCR5-
Δ32/wt patients.
The reduced rate of viral replication, evolution and immune
deterioration was the most apparent for the CCR5-Δ32/wt patient D.
The CCR5-Δ32/wt patient A seems to evolve faster, though still at a
lower rate than the CCR5-wt/wt patients B and C. The higher virus
heterogeneity in the baseline sample of patient A compared to the
others and the clustering away of the sequences from patient A in the
baseline phylogenetic tree, might indicate that patient A was infected
a few months longer than the other patients at the time of his ﬁrst
presentation and this could have inﬂuences the results obtained for
genetic evolution and intra-sample heterogeneity. However, the
observed differences in virus replication and genetic evolution
between the two CCR5-Δ32/wt patients as well as between the two
CCR5-wt/wt patients can also be seen as an indication for the
interference of other host factors.
In adults, substitutions in a partial env fragment are supposed to
accumulate at a rate of approximately 1% per year (Shankarappa et al.,
1999). Taken into account a delay in virus evolution during the one
year HAART, the evolutionary rates obtained for the patients with the
Fig. 3. Phylogenetic trees for the V1–V4 env sequences obtained for the samples collected at the ﬁrst visit (baseline) (A) and 3 years after the HAART interruption (B). The bar denotes
1% nucleotide diversity for panel A and B. ◆: Patient A RNA sequences; ◊: Patient A DNA sequences; ▪: Patient B RNA sequences; □: Patient B DNA sequences; ▴: Patient C RNA
sequences; ▵: Patient C DNA sequences; ●: Patient D RNA sequences; ○: Patient D DNA sequences.
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Fig. 3 (continued).
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Fig. 4. Genetic evolution after treatment interruption. The X-axis represents the mean pairwise genetic distances between baseline sequences and the sequences for each time point
after treatment interruption. The Y-axis shows the collection day, with day 0 = baseline. ◊ Patient A; □ Patient B; ▵ Patient C";; ○ Patient D.
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1.26%/yr and 0.97%/yr). A much slower evolutionary rate (resp 0.48%/
yr and 0.49%/yr) was seen in the individuals with a 32-bp deletion in
the CCR5 gene, patients A and D, correlating with the low viral load.
Although the relation between low genetic diversity and low viral load
or slow clinical progression is generally accepted (Mani et al., 2002;
Markham et al., 1998; Mikhail et al., 2005; Sutthent et al., 1998), some
reports have described an inverse relationship between viral load or
clinical progression and genetic diversity (Essajee et al., 1999;
Ganeshan et al., 1997; Liu et al., 1997; Wolinsky et al., 1996).
Besides point mutations, extensive insertions and deletions were
observed in the env gene, especially in the V1–V2 region. A remarkable
observation is the increase of the env fragment length over time in 3 of
the 4 patients. Only the non-progressing patient D conserved the
original fragment length. The meaning of this observation is unclear.
The results of this study also revealed a comparable genetic
diversity and a close intermingling of the PBMC-derived DNA and the
plasma derived RNA sequences. This ﬁnding indicates that PBMC-
derived viral DNA can adequately reﬂect the potential of replicative
competent viruses that is available and proves that our results are not
inﬂuenced by an overrepresentation of defective sequences.
All 4 subjects received ART for one year started within 6 months of
acute infection. Although there was a treatment bias, with the two
CCR5-Δ32/wt patients receiving a NRTIs based regimen (3TC+AZT
+ABC) and the two CCR5-wt/wt patients receiving a PI based regimen
(3TC+AZT+LPV/NFV), there are no reasons to believe that these
differences inﬂuenced the further disease course, though we cannot
exclude that the HAART has further reduced the already lower rate of
viral evolution in individuals with CCR5 delta-32 mutation. At the
time of initiation, early ART was supposed to allow preservation of the
HIV-1 speciﬁc proliferative response and improve the control of the
virus after treatment interruption. Today only few studies have
conﬁrmed this hypothesis (Rosenberg et al., 2000).
In conclusion, the results of this study show the different rate of
genetic evolution of a nearly identical virus in different hosts and
demonstrate a correlation between genetic evolution, viral load and
CCR5 genotype. Two individuals with a CCR5-Δ32/wt genotype had
less HIV-1 viremia and a slower genetic evolution of the virus
compared to the 2 individuals with a CCR5-wt/wt genotype. These
results are in agreement with the hypothesis that the viral replicative
capacity has an important inﬂuence on virus variability, at least in the
early stages of infection. But individual differences in viremia, genetic
variability and ﬂuctuations of CD4+ T cell numbers, irrespective of theCCR5 genotype, point to the additional inﬂuence of other host factors
in the disease process.
Materials and methods
Study subjects
Four HIV-1 infected individuals, from the Aids Reference Centre
(ARC) of the Ghent University Hospital, Belgium, were recognized as
being infected with closely related HIV-1 strains after phylogenetic
analysis of the reverse transcriptase and protease gene. All 4 subjects
were infected through homosexual contact. They all had a regular HIV
screening performed allowing a very precise estimation of the
infection date. Two of them experienced a period of inﬂuenza-like
illness, preceding a positive HIV test. Subject C was the source of
infection for both subjects B and D. Transmission occurred at a time
when subject C was himself acutely infected but still unaware of his
HIV status.
From patient A it was known that he had a sexual contact with
subject B but according to his information this contact dated from a
time when subject B was still HIV negative. Subject A had frequent
anonymous contacts and tracing the real source of his infection was
therefore difﬁcult.
All four patients were acutely infected at the time of their ﬁrst
consultation and a ﬁrst sample was drawn within six months of the
presumed infection date. All four individuals participated in a clinical
study aimed at evaluating the immunological and virological beneﬁts
of a one-year course of ART initiated within 6 months after infection.
Patient C suffered from other sexually transmitted infections (STD)
during the follow-up period (Syphilis, HBV, HCV, Lymphogranuloma
venereum).
The patients signed an informed consent form for participation in
this study and the project was approved by the Ethical Committee of
the institution.
Samples
EDTA blood samples were collected regularly. The plasma fraction
was stored at −70 °C. Peripheral bloodmononuclear cells (PBMC)were
recovered by centrifugation on a Ficoll-Hypaque gradient and either
stored at −70 °C or cryopreserved in liquid nitrogen. Phylogenetic
analysis was performed on PBMC-derived DNA sequences of samples
collected at different time points between the initial presentation in
221K. Chalmet et al. / Virology 379 (2008) 213–222the clinic (day 0) and 4 years thereafter (3 years after treatment
interruption) and on plasma derived RNA sequences from blood
samples collected at day 0 and at day 1593, 1433, 1551 and 1372 for
patients A, B, C and D respectively.
Quantiﬁcation of RNA plasma viral load
Plasma HIV-1 RNA was quantiﬁed with the Amplicor HIV Monitor
test kit v1.5 (Roche Diagnostics Systems, Basel, Switzerland). The
lower limit of detection of this assay is 50 RNA copies/ml. The CD4+ T
cell count was performed by ﬂow cytometry, using the FACScan
cytoﬂuorometer and the Cellquest software (Beckton Dickinson
Mountain View, California, USA), on freshly drawn blood samples.
Absolute CD4+ T cell numbers were expressed per microliter.
Detection of the CCR-5 deletion
The presence of a 32-bp deletion in the CCR-5 gene was assessed by
amplifying a 239-bp fragment ﬂanking the described 32-nucleotide
deletion in the CCR-5 gene with primers 5′-GATAGGTACCTGG-
CTGTCGTCCAT-3′ (sense, position 612 to 635) and 5′-AGATAGTCATCTT-
GGGGCTGGT-3′ (antisense, position 829 to 850) as described (Husman
et al., 1997). PCR products were analysed on a 3.5% agarose gel. To
conﬁrm the presence of the deletion, the bands in the agarose gel were
sliced out and a sequencing reaction was performed using the same
primers as the ones used for PCR ampliﬁcation.
Population envelope sequencing of plasma viral RNA
Viral RNA was extracted from 500 μl plasma with the High Pure
nucleic acid kit (Roche Molecular Biochemicals, Mannheim, Germany).
An outer env RT-PCR product was obtained using the Titan One tube RT-
PCR system (RocheMolecular Biochemicals, Mannheim, Germany) with
0.1 μM of the forward primer (5′-GAGGATATAATCAGTTTATGG-3′) and
the reverse primer (5′-GGTGGGTGCTATTCCTAATGG-3′). Two μl of the
outer RT-PCR product was subsequently used for a nested ampliﬁcation
with the primers 5′-GATCAAAGCCTAAAGCCATG-3′ and 5′-ACTTCTC-
CAATTGTCCCTCATAT-3. The second-round PCR was carried out using
Taq polymerase (Applied Biosystems Incorporated, Foster City, CA).
Direct sequencing of both sense and antisense strands was done with
the BigDye®Terminator Cycle Sequencing kit v. 3.1 (Applied Biosystems,
Foster City, California, USA) using the inner ampliﬁcation primers and
two internal primers: 5′-AATTCCATGTGTACATTGTACTG-3′ and 5′-
TATTGTGCYCCRGCTGGTTTTGC-3′. Sequencing reaction products were
analysed on an ABI 310 Genetic Analyser (Applied Biosystems). A
relatively conserved fragment comprising the C2 andV3 region (300 bp)
was cut out of the obtained sequences, aligned manually and used for
phylogenetic analysis of the population env sequences from different
subtype B infected patients from the clinic.
DNA extraction, limiting dilution PCR and single genome sequencing
DNAwas extracted from thawed PBMC using the QIAamp Blood Kit
(QIAGEN GmbH, Hilden, Germany). After extraction, all DNA samples
were diluted tenfold. Nested-PCR ampliﬁcation of a fragment
spanning the V1 to V4 region of the env gene (nucleotide positions
6591 to 7607 in the HIV-HXB2 genome) was performed using the
same primers as described for the population RNA sequencing. The
lower limit of detection of the PCR assay was equivalent to 1 copy per
reaction.
Approximately 40 identical PCR reactions were run for each
tenfold diluted sample. If less than two-third of those reactions were
found positive, the PCR products were selected for sequence analysis.
Both positive and negative controls were included in all PCR assays to
assess the sensitivity of the reaction and to detect possible
contamination. PCR and sequencing reactions were performed forone sample at a time to avoid mixing up of samples from different
time periods or from different subjects. Direct sequencing of both
sense and antisense strands was done as described above with the
BigDye® Terminator Cycle Sequencing kit v. 3.1 (Applied Biosystems,
Foster City, California, USA). All sequencing products for which
inspection of the electropherograms revealed nucleotide-mixtures at
one or more positions were withdrawn from further analysis. At least
10 single cell PCR products were sequenced per sample. The whole
sequenced fragment (approximately 1014 bp) was used for phyloge-
netic analysis.
RNA extraction, ampliﬁcation and clonal sequencing
RNA was extracted from plasma using the automated QIAamp
Virus BioRobot MDx extraction platform (Qiagen, Hilden, Germany).
V1–V4 env amplicons were generated by one step RT-PCR using
primers Env-6210F (nt 6221–6245 on JR-CSF, Genbank accession
number M38429) and Env-R3 (nt 7507–7527 on JR-CSF) and Super-
Script™ III RT/Platinum® Taq High Fidelity (Invitrogen, Paisley, United
Kingdom). Reactions were performed in sevenfold and amplicons
were pooled and agarose gel puriﬁed (QiaQuick Gel Extraction kit,
Qiagen). V1–V4 env amplicons were cloned in pCR4-TOPO vector and
transformed into competent TOP10 E. coli cells according to the
manufacturer's recommendations (TOPO TA Cloning® Kit, Invitrogen).
Individual colonies were picked for further analysis using the
QpExpression robot (Genetix Limited, Hampshire, United Kingdom).
V1–V4-containing TOPO plasmids were ampliﬁed by rolling circle
ampliﬁcation using the illustra TempliPhi DNA ampliﬁcation kit (GE
Healthcare, Vilvoorde, Belgium) according to the manufacturer's
instructions. These amplicons served as a template for sequencing.
Sequencing reactions were prepared using the BigDye® Terminator
Cycle Sequencing kit v. 3.1 (Applied Biosystems, Foster City, California,
USA) with primers T3 (5′-AATTAACCCTCACTAAAGGG-3′) and T7 (5′-
TAATACGACTCACTATAGGG-3′). Sequencing products were run on an
ABI3730xl automated sequencer. Sequence editing and contig assem-
bly were performed using SeqScape v2.5 (Applied Biosystems
Incorporated, Foster City, CA).
Sequence analysis
Nucleotide sequences were assembled using the BioEdit package
(Hall, 1999). Sequences were aligned using Clustal W with manual
correction (Thompson et al., 1994). Nucleotide gaps were assigned
after amino acid conversion to maintain translation integrity.
The best ﬁtting nucleotide-substitution model was selected
according to the Aikaike Information Criterium (AIC) using Modeltest
v3.7 (Posada and Crandall, 1998). Phylogenetic trees were recon-
structed in PAUP⁎ v4.0b10 (Phylogenetic Analysis Using Parsimony
(⁎and other methods), version 4, Sinauer Associates, Sunderland,
Massachusetts, http://paup.csit.fsu.edu/), starting from a stepwise-
addition tree with random addition order under a heuristic maximum
likelihood search that implemented tree bisection and reconnection
(TBR). Bootstrap analysis was performed using the above mentioned
conditions on 100 replicates. The tree in Fig. 1 was constructed based
on the 300-bp C2–V3 sequence using the sequence of patient P 9539,
infected with a subtype A virus, as outgroup. The trees in Fig. 3 were
constructed using the V1–V4 sequences (approximately 1014 bp)
obtained after limiting dilution sequencing or clonal sequencing. The
trees were rooted using the baseline consensus sequence as outgroup.
Tree diagrams were plotted with Treeview (Page, 1996).
Based on the amino acid sequence of the V3 loop, the PSSM
bioinformatics program (http://mullinslab.microbiol.washington.edu/
computing/pssm/) predicted CCR5 use for all viral strains isolated at
baseline (Jensen et al., 2003). For the samples collected at later time
points minor variants with a predicted CXCR4 tropismwere seen only
in the last two samples collected from patient B.
222 K. Chalmet et al. / Virology 379 (2008) 213–222Statistical analysis
The t test was used for the comparison of mean pairwise genetic
distances.
The ANOVA test was used for the comparison of regression lines.
For all tests p-values of b0.05 were considered statistically signiﬁcant.
Statistical analysis was performed with StatistiXL 1.8.
Nucleotide sequences
The sequences obtained during this study received Genbank
accession numbers genbank:EU008093 to genbank:EU008328 and
genbank:EU846607 to genbank:EU846981.
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